Positron emission tomography neuroimaging for a better understanding of the biology of ADHD.

PET Department, CERMEP-Imagerie du Vivant, 69003 Lyon, France.
Neuropharmacology (Impact Factor: 4.82). 09/2009; 57(7-8):601-7. DOI: 10.1016/j.neuropharm.2009.08.001
Source: PubMed

ABSTRACT Attention-deficit/hyperactivity disorder (ADHD) is a neurobehavioral disorder characterized by inappropriate symptoms of inattention, impulsivity and motor restlessness. Converging data from neuropsychological, genetic, neurochemical and pharmacological studies have implicated fronto-striatal network abnormalities as the likely cause of ADHD. The functional imaging field has evolved rapidly providing unprecedented tools to examine questions regarding the pathophysiology of ADHD and the biological effects of medications used to treat it. Positron emission tomography (PET) provides unique quantitative information on the spatial resolution of radiolabelled molecules in the brain of patients or healthy subjects allowing the longitudinal assessment of physiological parameters such as binding potential over extended periods of time. The main goal of this review is to provide an overview of PET studies performed in ADHD patients, discuss their relative strengths and weaknesses and show how they can complement one another to enable a better understanding of the neurobiology and the neuropharmacology of this disease.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Attention-deficit/hyperactivity disorder (ADHD) is a complex and heterogeneous disorder that is characterized not only by cognitive deficits but also by affective dysfunctions, both motivational and emotional. Nevertheless, the neural bases of affective dysfunctions have barely been explored in relation to this disorder, in contrast to extensive research that examined the neural correlates of its main cognitive deficits (attention, response inhibition and working memory). This article reviews the available data regarding the neurobiological substrates of motivational and emotional alterations showed by children, adolescents and adults with ADHD. Practical implications derived from these data are discussed and future research directions from affective neuroscience are suggested.
    Escritos de Psicología (Internet). 04/2010; 3(2):17-29.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The origin of ADHD is multifactorial and both the aetiology and pathophysiology of ADHD are as yet incompletely understood. The monoamine deficit hypothesis of ADHD postulates a dysbalance in the interaction of the neurotransmitters dopamine, noradrenaline and serotonin. Pathophysiological mechanisms involved in ADHD include alterations in fronto-striatal circuits. The currently proposed animal models of ADHD are heterogeneous with regard to their pathophysiological alterations and their ability to mimic behavioural symptoms and to predict response to medication. Some evidence points to a genetic basis for ADHD which is likely to involve many genes of small individual effects. In summary, specific neurobiological substrates of ADHD are unknown and multiple genetic and environmental factors appear to act together to create a spectrum of neurobiological liability.
    Fortschritte der Neurologie · Psychiatrie 01/2014; 82(1):9-29. · 0.85 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Attention deficit/hyperactivity disorder (ADHD) is present in 8% to 12% of children, and 4% of adults worldwide. Children with ADHD can have learning impairments, poor selfesteem, social dysfunction, and an increased risk of substance abuse, including cigarette smoking. Overall, the rate of treatment with medication for patients with ADHD has been increasing since 2008, with ≥ 2 million children now being treated with stimulants. The rise of adolescent prescription ADHD medication abuse has occurred along with a concomitant increase of stimulant medication availability. Of adults presenting with a substance use disorder (SUD), 20% to 30% have concurrent ADHD, and 20% to 40% of adults with ADHD have a history of SUD. Following a brief review of the etiology of ADHD, its diagnosis and treatment, we focus on the benefits of early and appropriate testing for a predisposition to ADHD. We suggest that by genotyping patients for a number of known, associated dopaminergic polymorphisms, especially at an early age, misdiagnoses and/or over-diagnosis can be reduced. Ethical and legal issues of early genotyping are considered. As many as 30% of individuals with ADHD are estimated to either have secondary side-effects or are not responsive to stimulant medication. We also consider the benefits of non-stimulant medication and alternative treatment modalities, which include diet, herbal medications, iron supplementation, and neurofeedback. With the goals of improving treatment of patients with ADHD and SUD prevention, we encourage further work in both genetic diagnosis and novel treatment approaches.
    Postgraduate Medicine 01/2014; 126(1):153-77. · 1.97 Impact Factor

Full-text (2 Sources)

Available from
May 16, 2014

View other sources